Business
Advanced Biomed Inc. Announces Disposal of its Hong Kong Subsidiary
Tainan City, Taiwan, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”, “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced that on December 23, 2025, it entered into an agreement (the “Agreement”) with an unrelated third party, Wei Ha Hui (the “Buyer”), pursuant to which the Company agreed to sell 100% of the issued and outstanding
About this update from Advanced Biomed Inc.
[{"type":"image","alt":"Advanced Biomed Inc.","displaySize":"","headline":null,"caption":"Advanced Biomed Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":143,"url":"https://media.zenfs.com/en/globenewswire.com/393c670c899a590f026f8c84b8777f43"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/faMVLMhp_8Nwf8VXbjmfNA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIwMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/393c670c899a590f026f8c84b8777f43","width":300,"height":143}},"lazy":false},{"type":"text","content":"Tainan City, Taiwan, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”, “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced that on December 23, 2025, it entered into an agreement (the “Agreement”) with an unrelated third party, Wei Ha Hui (the “Buyer”), pursuant to which the Company agreed to sell 100% of the issued and outstanding shares of Advanced Biomed (HK) Limited, a Hong Kong company and a wholly owned subsidiary of the Company (the “Hong Kong Subsidiary”), for an aggregate purchase price of US$23,000 based on a valuation report commissioned by the Company, subject to the terms and conditions set forth in the Agreement.","length":800,"tagName":"p"},{"type":"text","content":"All intellectual property owned by the Hong Kong subsidiary, including intellectual property owned by Shanghai Sglcell Biotech Co., Ltd., a wholly owned subsidiary of the Hong Kong subsidiary, was transferred to the Buyer at the closing of this transaction on December 23, 2025.","length":278,"tagName":"p"},{"type":"text","content":"Dr. Yi Lu, CEO of the Company, commented: “In light of evolving regulatory requirements on clinical trials and data in China, and to accelerate development and commercialization of our products and solutions, we decided to divest the assets of Hong Kong and Shanghai subsidiaries. All clinical trials will now be centralized and conducted through our Taiwan subsidiary, which we believe will be part of our strategic realignment.”","length":430,"tagName":"p"},{"type":"text","content":"About Advanced Biomed Inc. ","length":26,"tagName":"p"},{"type":"text","content":"Advanced Biomed Inc. is a Nevada corporation specializing in innovative biomedic...